首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Blood Cancer Journal

Blood Cancer Journal杂志,由Springer Nature出版,于2011年创刊,1 issue/year,出版语言English,ISSN:2044-5385,E-ISSN:2044-5385。

投稿咨询
Blood Cancer Journal
Blood Cancer Journal
Blood Cancer Journal
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
13.8
CiteScore
16.2
期刊收录
SCI、SCIE

Blood Cancer Journal(中文译名:《血癌杂志》),ISSN:2044-5385,EISSN:2044-5385,是Springer Nature出版的国际性学术期刊,创刊于2011年,以1 issue/year形式稳定发行,2026年总发文量约105篇。该刊采用OA开放访问,学科归属为ONCOLOGY。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达13.8,2025年期刊CiteScore为16.2,2025年期刊自引率约3.6%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Blood Cancer Journal长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期>12周,或约稿,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAItaly、GERMANY (FED REP GER)、France、Spain、England、CHINA MAINLAND等为核心发文国家与地区;MAYO CLINICHARVARD UNIVERSITY、UNIVERSITY OF TEXAS SYSTEM、HELMHOLTZ ASSOCIATION、RUPRECHT KARLS UNIVERSITY HEIDELBERG、UNIVERSITY OF FLORENCE、NATIONAL & KAPODISTRIAN UNIVERSITY OF ATHENS等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学 HEMATOLOGY 血液学
1区 1区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学 ONCOLOGY 肿瘤学
1区 1区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
HEMATOLOGY 血液学 ONCOLOGY 肿瘤学
1区 1区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 6 / 103

94.7

学科:ONCOLOGY SCIE Q1 24 / 333

92.9

学科:HEMATOLOGY SCIE Q1 7 / 103

93.69

学科:ONCOLOGY SCIE Q1 29 / 333

91.44

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q1 5 / 97

95.4

学科:ONCOLOGY SCIE Q1 18 / 322

94.6

学科:HEMATOLOGY SCIE Q1 8 / 97

92.27

学科:ONCOLOGY SCIE Q1 28 / 322

91.46


中国学者近期发文

1
Utility of dual assessment of cyTRBC1 and cyTRBC2 by flow cytometry for identifying clonality in sCD3-negative to dimly expressing T cell

Author:Li, Mingyong; Fu, Jun; Li, Yanxin; Fan, Xiaoming; Zhang, Liuyun; Zhou, Lingjie; Zhang, Jin; Zhang, Juan; Xi, Qian

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01483-1

2
Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: a single-arm, open-label, phase Ia/Ib stud

Author:Yang, Fan; Liu, Rui; Fu, Zhonghua; Guo, Yuelu; Ma, Lixia; Cao, Miaomiao; Deng, Biping; Chang, Alex H.; Wu, Haifeng; Gan, Shilin; Chen, Chen; Ke, Xiaoyan; Hu, Kai

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01476-0

3
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myelom

Author:Kumar, Shaji; Jagannath, Sundar; Weisel, Katja C.; Rosinol, Laura; Leleu, Xavier; Dimopoulos, Meletios-Athanasios; Kastritis, Efstathios; Siegel, David S.; Monge, Jorge; Du, Juan; de la Rubia, Javier; Asensi Canto, Pedro; Lee, Jae Hoon; Mateos, Maria-Victoria; Puertas, Borja; Gozzetti, Alessandro; Dytfeld, Dominik; Ocio, Enrique M.; Blade, Joan; Ozaki, Shuji; Beksac, Meral; Escalante, Fernando; Nagaraj, Madhu; Hassan, Rafla; Bonar, Nicolle; Spin, Paul; Shokoohi, Mostafa; Siddiqui, Muhaimen; Wang, Di; Hou, Kevin; West, Michael E. D.; Hampp, Christian; Green, Jeannette; Humblet, Olivier; Breskin, Alexander; Harnett, James; Ge, Wenzhen; Sobel, Rachel E.; Jalbert, Jessica J.; Kroog, Glenn S.; Rodriguez Lorenc, Karen; Ma, Qiufei; Durie, Brian G. M

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01466-2

4
Efficacy and safety of short-course blinatumomab in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemi

Author:Liu, Ge; Zhou, Yile; Lou, Yinjun; Ai, Hao; Mao, Liping; Wang, Qian; Wu, Hongfei; Tong, Hongyan; Wei, Xudong; Jin, Jie; Wang, Huafeng; Yin, Qingsong

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01460-8

5
Imatinib and nilotinib are equally successful in achieving therapy-free remissio

Author:Cheng, Fang; Wang, Yu; Yang, Yunfan; Du, Xin; Zhu, Yu; Weng, Jianyu; Xu, Na; Huang, Jian; Liu, Zhenfang; Ren, Hongbo; Zhao, Huifang; Zhu, Huanling; Jiang, Qian; Zhang, Yanli; Li, Weiming

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01462-6

6
Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26

Author:Wei, Juying; Cai, Qingqing; Zhang, Liling; Zou, Liqun; Li, Zengjun; Zhou, Keshu; Wu, Huijing; Qiu, Lihua; Su, Liping; Ding, Kaiyang; Zhou, Hui; Yu, Li; Li, Fei; Li, Wenyu; Lin, Li'e; Xiao, Qing; Wang, Erhua; Jing, Hongmei; Zheng, Meifang; Zhang, Hongyu; Gao, Yuhuan; Gao, Da; Chen, Lijia; Jin, Jie

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01452-8

7
Anti-PD-1 antibody combined with P-GEMOX chemotherapy versus P-GEMOX chemotherapy with or without autologous stem-cell transplantation for previously untreated advanced natural killer/T cell lymphoma: a retrospective cohort stud

Author:Zou, Qihua; Cao, Yi; Wang, Liang; Li, Wuping; Yin, Qingsong; Wu, Yudan; Jing, Hongmei; Peng, Zhigang; Sun, Xiuhua; Rao, Jun; Chen, Ying; Zhang, Hongyu; Zeng, Dongfeng; Li, Bingzong; Zhao, Ying; Zhang, Xudong; Zhang, Yuchen; Gao, Yan; Bai, Bing; Xia, Yi; Fang, Yu; Chen, Zouxiang; Nie, Man; Fang, Xiaojie; Bai, Shenrui; Huang, Huiqiang; Cai, Qingqing; Cai, Jun

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01459-1

8
Long-term outcomes of autologous stem cell transplantation for AL amyloidosis: a 15-year experience from a Chinese referral center and a comparison of different era

Author:Liu, Mengnan; Guo, Jinzhou; Chen, Wencui; Wu, Xiaomei; Xu, Weiwei; Huang, Xianghua

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01464-4

9
Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancie

Author:Li, Tingting; Wang, Chaoyu; Xiao, Qing; Zhang, Xiaomei; Yang, Zailin; Li, Jun; Liu, Yao

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01453-7

10
Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 tria

Author:Shen, Hao-Rui; Wu, Jia-Zhu; Yin, Hua; Du, Kai-Xin; Sibusiso, Luthuli; Wu, Yi-Fan; Hua, Wei; Li, Yue; Kong, Yi-Lin; Zhang, Xin-Yu; Gao, Rui; Li, Jian-Yong; Wang, Li; Liang, Jin-Hua; Xu, Wei

Journal: BLOOD CANCER JOURNAL. 2026; Vol. 16, Issue 1, pp. -. DOI: 10.1038/s41408-026-01450-w


在线咨询

Blood Cancer Journal

国际简称:BLOOD CANCER J参考译名:血癌杂志

年发文量:105 CiteScore:16.2 是否预警:否 Gold OA文章占比:100.00% 研究类文章占比:92.38%

杂志社联系方式:CAMPUS, 4 CRINAN ST, LONDON, ENGLAND, N1 9XW

Blood Cancer Journal